Onco-Summaries: Daily Oncology Updates at a Glance

23/07/2026

---

• Phase 3 MonumenTAL-6 study shows PFS benefit for TECVAYLI + TALVEY combo in Multiple Myeloma

• Epcoritamab Phase 3 DLBCL trial failed to meet OS endpoint

---

Phase 3 MonumenTAL-6 study shows PFS benefit for TECVAYLI + TALVEY combo in Multiple Myeloma (Ref)

Johnson & Johnson announced positive topline results from the Phase 3 MonumenTAL-6 trial of TECVAYLI and TALVEY combinations in relapsed/refractory multiple myeloma patients.

MonumenTAL-6 trial evaluated TECVAYLI® (teclistamab-cqyv) + TALVEY® (talquetamab-tgvs), a BCMA and GPRC5D dual antigen targeting regimen, and TALVEY® + pomalidomide vs investigator’s choice standard of care in adult patients with relapsed or refractory multiple myeloma (RRMM) who received 1 to 4 prior lines of therapy, including an anti-CD38 antibody and lenalidomide

• TECVAYLI + TALVEY (Tec-Tal): 89% reduction in risk of disease progression or death (HR 0.11) and 62% reduction in risk of death (HR 0.38), the lowest hazard ratio recorded in any Phase 3 bispecific therapy in relapsed/refractory multiple myeloma

• TALVEY + pomalidomide (Tal-P): 73% reduction in risk of progression or death (HR 0.27)

• Both arms met the primary endpoint of PFS with statistically significant improvements vs standard of care

• Safety profiles for both combination arms were consistent with each drug's known individual safety profile

Independent Data Monitoring Committee recommended early unblinding due to strong efficacy

The full results of the Phase 3 MonumenTAL-6 study will be presented at a future major medical meeting and shared with global health authorities

Return to Top

Epcoritamab Phase 3 DLBCL trial failed to meet OS endpoint (Ref)

Genmab and AbbVie announced a formal clarification regarding the Phase 3 EPCORE DLBCL-1 trial, confirming that overall survival, the sole US primary endpoint, did not reach statistical significance in adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who were ineligible for autologous stem cell transplantation

The trial evaluated subcutaneous epcoritamab (DuoBody®-CD3xCD20) monotherapy vs investigator's choice chemoimmunotherapy (R-GemOx or BR) in relapsed/refractory DLBCL patients ineligible for stem cell transplant

Results will be submitted for peer-reviewed publication

Return to Top